To learn more about what you can expect from your Skyrizi treatment, talk with your doctor. Disclaimer: Healthline has made every effort to make certain that all information is factually correct ...

MONTREAL, March 4, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ...

For the ongoing quarter, AbbVie sees adjusted EPS between $2.47 and $2.51 on revenue of about $12.8 billion, Reents told ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for immunology powerhouses Skyrizi and Rinvoq by $4 billion. The company now projects more than ...

AbbVie ABBV announced the submission of regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of its drug Skyrizi (risankizumab) for a new indication, moderately ...

One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...

Skyrizi was in fact up two places in June from May, with AbbVie spending $26.6 million on all TV ads for the drug last month. That was $1.3 million more than it spent on Rinvoq, its JAK inhibitor ...

16.2%). Perspective from Shubha Bhat, PharmD, MS, FCCP, BCACP Although Skyrizi was noninferior to Stelara in clinical remission at week 24, it was superior in endoscopic remission at week 48 in ...